首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1547376

全球溶瘤病毒免疫疗法市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

Global Oncolytic Virus Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球溶瘤病毒免疫治疗市场需求预计将从2023年的1.6635亿美元达到近9.756亿美元的市场规模，2024-2032年研究期间的复合年增长率为21.72%。

溶瘤病毒免疫疗法涉及针对特定癌细胞进行感染和破坏的基因改造病毒，同时刺激抗肿瘤免疫反应。这些溶瘤病毒被设计为在癌细胞内复製，导致细胞裂解并释放肿瘤抗原，激活免疫系统以瞄准并消除剩余的癌细胞。这种方法直接减轻肿瘤负担并增强人体对癌症的自然免疫反应。它正在针对各种癌症进行探索，为化疗和放疗等传统疗法提供有希望的补充治疗，并有可能提高疗效并减少副作用。

市场动态

全球癌症发生率不断上升，对创新和有效的治疗方案产生了显着需求，而溶瘤病毒免疫疗法成为一种有前途的方法。基因工程和病毒学的进步使得能够开发出更有效、更有针对性的溶瘤病毒，从而提高其治疗功效和安全性。此外，人们越来越认识到并接受免疫疗法作为一种可行的癌症治疗方法，这也促进了溶瘤病毒疗法的采用。製药公司和研究机构对研发的大力投资正在加速这些疗法的临床试验和商业化。突破性疗法的监管支持和快速批准正在进一步推动市场成长。

溶瘤病毒刺激针对癌细胞的强大免疫反应的能力，加上它们与检查点抑制剂和传统疗法等其他治疗方法一起使用的潜力，正在推动其临床应用。此外，生物技术公司和学术机构之间的合作和伙伴关係促进创新并扩大治疗管道。个人化医疗的整体推动力，即根据患者个别情况量身订做治疗方案，也支持了溶瘤病毒免疫治疗市场的成长。然而，潜在的安全问题、高昂的开发成本以及临床试验和监管审批的复杂性可能会阻碍溶瘤病毒免疫疗法市场未来几年的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球溶瘤病毒免疫治疗市场的每个细分市场进行了包容性评估。溶瘤病毒免疫治疗市场行业的成长和趋势为本研究提供了整体方法。

市场区隔

溶瘤病毒免疫治疗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按类型

单纯疱疹病毒
痘苗病毒
腺病毒
呼肠孤病毒
其他的

依给药途径

瘤内
静脉

按申请

黑色素瘤
非小细胞肺癌（NSCLC）
胰腺癌
乳癌
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲溶瘤病毒免疫治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。溶瘤病毒免疫治疗市场的主要参与者包括 Merck & Co. Inc. (Viralytics Limited)、Amgen Inc.、上海三维生物科技有限公司、TILT Biotherapeutics、Oncorus Inc.、Replimune Group Inc.、Oncolys Biopharma Inc.、 Sorrento Therapeutics Inc.、Oncolytics Biotech Inc.、SillaJen Inc.。产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：溶瘤病毒免疫治疗市场公司的竞争格局

溶瘤病毒免疫治疗市场市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
Merck & Co. Inc. (Viralytics Limited)

公司概况
公司收入
产品
最新动态

Amgen Inc.

公司概况
公司收入
产品
最新动态

Shanghai Sunway Biotech Co. Ltd.

公司概况
公司收入
产品
最新动态

TILT Biotherapeutics

公司概况
公司收入
产品
最新动态

Oncorus Inc.

公司概况
公司收入
产品
最新动态

Replimune Group Inc.

公司概况
公司收入
产品
最新动态

Oncolys Biopharma Inc.

公司概况
公司收入
产品
最新动态

Sorrento Therapeutics Inc.

公司概况
公司收入
产品
最新动态

Oncolytics Biotech Inc.

公司概况
公司收入
产品
最新动态

SillaJen Inc

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR11215755

The global demand for Oncolytic Virus Immunotherapy Market is presumed to reach the market size of nearly USD 975.6 Million by 2032 from USD 166.35 Million in 2023 with a CAGR of 21.72% under the study period 2024-2032.

Oncolytic virus immunotherapy involves genetically modified viruses that target specific cancer cells for infection and destruction of cancer cells while stimulating an anti-tumor immune response. These oncolytic viruses are engineered to replicate within cancer cells, causing cell lysis and releasing tumor antigens, activating the immune system to target and eliminate remaining cancer cells. This approach directly reduces tumor burden and enhances the body's natural immune response against cancer. It is being explored for various cancers, offering a promising complementary treatment to traditional therapies like chemotherapy and radiation, with the potential for improved efficacy and reduced side effects.

MARKET DYNAMICS

The increasing incidence of cancer worldwide has generated a notable demand for innovative and effective treatment options, with oncolytic virus immunotherapy emerging as a promising approach. Genetic engineering and virology advancements have enabled the development of more potent and targeted oncolytic viruses, enhancing their therapeutic efficacy and safety profile. Additionally, growing awareness and acceptance of immunotherapy as a viable cancer treatment are boosting the adoption of oncolytic virus therapies. Robust investment in research and development by pharmaceutical companies and research institutions is accelerating these therapies' clinical trials and commercialization. Regulatory support and fast-tracked approvals for breakthrough therapies are further propelling market growth.

The ability of oncolytic viruses to stimulate a robust immune response against cancer cells, combined with their potential to be used with other treatments, such as checkpoint inhibitors and traditional therapies, is driving their clinical application. Furthermore, collaborations and partnerships between biotech companies and academic institutions foster innovation and expand the therapeutic pipeline. The overall drive towards personalized medicine, where treatments are tailored to individual patient profiles, also supports the growth of the oncolytic virus immunotherapy market. However, potential safety concerns, high development costs, and the complexity of clinical trials and regulatory approvals may hinder the growth of the oncolytic virus immunotherapy market in the next few years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Oncolytic Virus Immunotherapy Market. The growth and trends of Oncolytic Virus Immunotherapy Market industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Oncolytic Virus Immunotherapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Herpes Simplex Virus
Vaccinia Virus
Adenovirus
Reovirus
Others

By Route of Administration

Intratumoral
Intravenous

By Application

Melanoma
Non-small Cell Lung Cancer (NSCLC)
Pancreatic Cancer
Breast Cancer
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Oncolytic Virus Immunotherapy Market market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Oncolytic Virus Immunotherapy market include Merck & Co. Inc. (Viralytics Limited), Amgen Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics, Oncorus Inc., Replimune Group Inc., Oncolys Biopharma Inc., Sorrento Therapeutics Inc., Oncolytics Biotech Inc., SillaJen Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Herpes Simplex Virus Historic and Forecast Sales By Regions
5.4. Vaccinia Virus Historic and Forecast Sales By Regions
5.5. Adenovirus Historic and Forecast Sales By Regions
5.6. Reovirus Historic and Forecast Sales By Regions
5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Intratumoral Historic and Forecast Sales By Regions
6.4. Intravenous Historic and Forecast Sales By Regions

7. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data Analysis By Application
7.3. Melanoma Historic and Forecast Sales By Regions
7.4. Non-small Cell Lung Cancer (NSCLC) Historic and Forecast Sales By Regions
7.5. Pancreatic Cancer Historic and Forecast Sales By Regions
7.6. Breast Cancer Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET COMPANIES

9.1. Oncolytic Virus Immunotherapy Market Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Merck & Co. Inc. (Viralytics Limited)
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Amgen Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Shanghai Sunway Biotech Co. Ltd.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. TILT Biotherapeutics
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Oncorus Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Replimune Group Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Oncolys Biopharma Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Sorrento Therapeutics Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Oncolytics Biotech Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. SillaJen Inc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments